Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan vs ACEI for post-MI heart failure reverse remodeling
ChiCTR2000039648Phase 4Recruiting
- Sponsor
- Department of Cardiology, Affiliated Hospital of Xuzhou Medical University
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sacubitril + valsartan in heart failure (HF) and myocardial infarction (MI) (2 arms), sponsored by Department of Cardiology, Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Left ventricular ejection fraction at 1 year, Left ventricular end-diastolic dimension at 1 year and 1 more. Started Nov 2020; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure (HF)myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2000039648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039648.